Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
11.12. | Overcoming the first hurdles: Navigating early phase challenges for biotechs | ||
11.12. | Relation-GSK to drive fibrotic and osteoarthritis developments | ||
11.12. | Better prevention and treatment options needed for genital herpes, WHO says | ||
11.12. | Lilly's £279m bet aims to boost UK life sciences sector | ||
11.12. | ASH 2024: J&J's Tecvayli shows promise in transplant-eligible NDMM patient | ||
11.12. | Dr Myles Greenberg becomes president and CEO of InCarda Therapeutics | ||
10.12. | ASH 2024: Regeneron's Ordspono faces challenges, but positive results signal hope | ||
10.12. | New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III | ||
10.12. | EMA validates Chiesi and Protalix's dose variation for Fabry disease | ||
10.12. | RSV prophylactic market to reach $6.2bn in 8MM by 2030 | ||
10.12. | Santhera's DMD therapy Agamree approved for NHS use after new price deal | ||
10.12. | Seres' SER-155 gains breakthrough status for BSIs reduction | ||
10.12. | FDA to review GSK's Nucala for COPD | ||
09.12. | Daiichi Sankyo secures breakthrough designation for NSCLC treatment | ||
09.12. | Citryll gains Series B funds to develop NET-targeting antibody | ||
09.12. | Bringing Engineering to a New Level: ZETA's Integrated Approach | ||
09.12. | Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill | ||
09.12. | Novo Holdings' acquisition of Catalent gains EC approval | ||
09.12. | Innovative Buffer Management Solutions: ZETA's Modular Buffer Inline Conditioning System | ||
09.12. | Priority FDA review given to AstraZeneca's Imfinzi sBLA for MIBC | ||
06.12. | FDA shares new draft guidance for accelerated approval | ||
06.12. | New study finds obesity costs US industry $347bn a year | ||
06.12. | Nature study finds obesity costs US industry $347bn a year | ||
06.12. | Cell and gene therapy companies must demonstrate strong value proposition for investment | ||
06.12. | Eli Lilly to invest $3bn in Wisconsin facility expansion |